$TCRT
Alaunos Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024126793 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.007M
YoY Change -71.87%
% of Gross Profit
Research & Development $143.0K
YoY Change -96.09%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $1.150M
YoY Change -86.73%
Operating Profit -$1.150M
YoY Change -86.73%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $23.00K
YoY Change -87.77%
Pretax Income -$1.127M
YoY Change -86.71%
Income Tax
% Of Pretax Income
Net Earnings -$1.127M
YoY Change -86.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$0.70
COMMON SHARES
Basic Shares Outstanding 1.601M 1.601M
Diluted Shares Outstanding 1.601M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.683M
YoY Change -85.86%
Cash & Equivalents $1.683M
Short-Term Investments
Other Short-Term Assets $1.867M
YoY Change 107.44%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $3.550M
YoY Change -72.41%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $3.550M
Total Long-Term Assets $0.00
Total Assets $3.550M
YoY Change -81.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $458.0K
YoY Change -64.71%
Accrued Expenses $368.0K
YoY Change -88.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $826.0K
YoY Change -82.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $826.0K
Total Long-Term Liabilities $0.00
Total Liabilities $826.0K
YoY Change -85.09%
SHAREHOLDERS EQUITY
Retained Earnings -$919.7M
YoY Change 1.3%
Common Stock $922.4M
YoY Change 0.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.724M
YoY Change
Total Liabilities & Shareholders Equity $3.550M
YoY Change -81.74%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.127M
YoY Change -86.7%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$781.0K
YoY Change -87.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -781.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -781.0K
YoY Change -87.76%
FREE CASH FLOW
Cash From Operating Activities -$781.0K
Capital Expenditures $0.00
Free Cash Flow -$781.0K
YoY Change -87.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
2617 Bissonnet Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 225
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77005
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
355-4099
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1601252
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1683000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6062000
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1867000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2198000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3550000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8261000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2024Q3 us-gaap Assets
Assets
3550000
CY2023Q4 us-gaap Assets
Assets
8263000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
458000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
616000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
368000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1340000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
826000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1956000
CY2024Q3 us-gaap Liabilities
Liabilities
826000
CY2023Q4 us-gaap Liabilities
Liabilities
1956000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601252
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601252
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601252
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601252
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
922426000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
922072000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-919704000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915767000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2724000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6307000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3550000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8263000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
143000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3656000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
448000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15346000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1007000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3578000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3615000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9791000
CY2024Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2023Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
245000
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
419000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
419000
CY2024Q3 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
0
CY2023Q3 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
1011000
tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
0
tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
1011000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1150000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8664000
us-gaap Operating Expenses
OperatingExpenses
4063000
us-gaap Operating Expenses
OperatingExpenses
26322000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1150000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8664000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4057000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26318000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1921000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
120000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
942000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
188000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-979000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1127000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8476000
us-gaap Net Income Loss
NetIncomeLoss
-3937000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.3
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.07
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1601252
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1601252
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1600306
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1600306
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1601252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1601252
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1598948
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1598948
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3771000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
80000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1127000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2724000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6307000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
354000
us-gaap Net Income Loss
NetIncomeLoss
-3937000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2724000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21650000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
726000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8476000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13900000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2550000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13900000
us-gaap Net Income Loss
NetIncomeLoss
-3937000
us-gaap Net Income Loss
NetIncomeLoss
-27297000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
2074000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1011000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1339000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
354000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
2550000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
0
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-1332000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
245000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-331000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
126000
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
0
tcrt Increase Decrease In Operating Deposits
IncreaseDecreaseInOperatingDeposits
42000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-159000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-92000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-972000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2258000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
0
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1575000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
472000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4379000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22757000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
197000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
18105000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
125000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18138000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4379000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41052000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6062000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52996000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1683000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11944000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
2063000
CY2023Q3 tcrt Strategic Advisor Name
StrategicAdvisorName
Cantor
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1700000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-919700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2024Q1 tcrt Pre Stock Split Shares Authorized
PreStockSplitSharesAuthorized
520000000
CY2024Q1 tcrt Post Stock Split Shares Authorized
PostStockSplitSharesAuthorized
34666667
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Second Charter Amendment became effective on January 31, 2024.
CY2024Q3 tcrt Pre Stock Split Shares Authorized
PreStockSplitSharesAuthorized
34666667
CY2024Q3 tcrt Post Stock Split Shares Authorized
PostStockSplitSharesAuthorized
5000000
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Third Charter Amendment became effective on July 17, 2024.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59792
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
238511
CY2023Q1 us-gaap Loss Contingency Name Of Plaintiff
LossContingencyNameOfPlaintiff
KBI Biopharma
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3200000
CY2023Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1000000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
80000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
726000
us-gaap Share Based Compensation
ShareBasedCompensation
354000
us-gaap Share Based Compensation
ShareBasedCompensation
2550000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.06
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
66
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
58.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
13289
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
24634
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
58.5
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0401
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0409
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0351
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0401
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1217
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9065
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1217
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.705
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8969
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9563
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
46589
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
268.5
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
13289
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26641
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
283.08
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
33237
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
153.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
20729
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
250.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M6D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
142745
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-126793-index-headers.html Edgar Link pending
0000950170-24-126793-index.html Edgar Link pending
0000950170-24-126793.txt Edgar Link pending
0000950170-24-126793-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20240930.htm Edgar Link pending
tcrt-20240930.xsd Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tcrt-20240930_htm.xml Edgar Link completed